Evaluation of anticancer properties and molecular mechanisms of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group

2017/25/N/NZ3/01039

Keywords

Descriptors

  • NZ1_1: Biologia molekularna
  • NZ3_1: Biologia komórki
  • NZ7_14: Farmacja, farmakoterapia, farmakologia

Panel

NZ3 – Cellular and developmental biology: cell biology, developmental biology, ageing biology, neurobiology

Host institution

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Voivodeship: łódzkie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr Angelika Agata Długosz-Pokorska

Number of co-investigators in the project: 2

Call

PRELUDIUM 13 – announced on 2017-03-15

Amount awarded
149 700 PLN
Project start date
2018-03-22
Project end date
2024-09-21
Project duration
78 months (the same as in the proposal)
Project status
Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (5)

  1. New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF-7 Cancer Cells.

    Authors:
    Angelika Długosz-Pokorska , Renata Perlikowska , Tomasz Janecki , Anna Janecka
    Academic press:
    Biologics: Targets and Therapy (year: 2023, volume: 17, pages: 69–83), Publisher: Dovepress
    Status:
    Published
    DOI:
    10.2147/BTT.S405080 – link to the publication
  2. New uracil analogs as downregulators of ABC transporters in 5-fluorouracil-resistant human leukemia HL-60 cell line.

    Authors:
    Długosz-Pokorska Angelika, Pięta Marlena, Janecki Tomasz, Janecka Anna
    Academic press:
    Molecular Biology Reports (year: 2019, volume: 46(6), pages: 5831-5839), Publisher: Springer Science+Business Media
    Status:
    Published
    DOI:
    10.1007/s11033-019-05017-w – link to the publication
  3. New uracil analog with exocyclic methylidene group as potential anticancer agent.

    Authors:
    Angelika Długosz-Pokorska, Joanna Drogosz, Marlena Pięta, Tomasz Janecki, Urszula Krajewska, Marek Mirowski, Anna Janecka
    Academic press:
    Anti-Cancer Agents in Medicinal Chemistry (year: 2020, volume: 20, pages: 359-368), Publisher: Bentham Science Publishers
    Status:
    Published
    DOI:
    10.2174/1871520619666191211104128 – link to the publication
  4. New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line

    Authors:
    Angelika Długosz-Pokorska, Marlena Pięta, Jacek Kędzia, Tomasz Janecki, Anna Janecka
    Academic press:
    BMC Pharmacology and Toxicology (year: 2020, volume: 21, pages: 46032), Publisher: Springer
    Status:
    Published
    DOI:
    10.1186/s40360-020-0397-4 – link to the publication
  5. New uracil analog as inhibitor/modulator of ABC transporters or/and NF‑κB in taxol‑resistant MCF‑7/Tx cell line

    Authors:
    Angelika Długosz‑Pokorska · Tomasz Janecki · Anna Janecka · Katarzyna Gach‑Janczak
    Academic press:
    Journal of Cancer Research and Clinical Oncology (year: 2024, volume: 150, pages: 46033), Publisher: Springer
    Status:
    Published
    DOI:
    10.1007/s00432-024-05833-z – link to the publication

Articles in post-conference publications (1)

  1. New Uracil Analog- U-359 can reverse resistance to Taxol in MCF-7 cancer cells

    Authors:
    Angelika Długosz-Pokorska, Renata Perlikowska, Tomasz Janecki, Anna Janecka
    Conference:
    the 5th BIO Congress (year: 2023, pages: 56), Publisher: Acta Biochmica Polonica
    Date:
    conference 13-16.09.2023
    Status:
    Published

« New search

Graphic design and implementation: Jakub Piotrowski